Publicaciones en colaboración con investigadores/as de Children's Hospital Colorado (2)

2023

  1. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

    The Lancet Child and Adolescent Health, Vol. 7, Núm. 3, pp. 180-189

2022

  1. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity

    New England Journal of Medicine